The Future of Healthcare Runs on AI-Powered Automation and Data — Here’s How One Company Is Making It a Reality

Healthcare is entering a new era filled with opportunity. Hospitals are exploring smarter ways to care for patients with the staff they have. Pharmaceutical companies are rethinking how to bring therapies to market with greater speed and precision. Across the industry, one theme is clear: AI-powered automation and data are unlocking solutions that make healthcare stronger, safer, and more sustainable.

At BioAdvance, we invest in companies that embrace these forces and turn them into growth. One of our portfolio companies, Bainbridge Health, is doing just that. Their model shows how technology can support hospitals and pharmaceutical innovators alike in building the next generation of healthcare systems.

Why Hospitals Are Ready for Automation

Hospitals are increasingly turning to technology to support staff and enhance care. Pharmacy workflows, once reliant on manual effort, are being transformed by AI-driven automation. Bainbridge Health's platform ensures safety, consistency, and efficiency in processes that are central to patient well-being.

This shift is happening quickly. Bainbridge Health's Med O.S.® platform is now active in over 600 hospital facilities covering more than 120,000 licensed beds across 43 states, representing year-over-year growth of over 100%. Some of the largest and most prominent Health Systems in the United States have recently joined their network, validating the platform's role in using AI-powered automation to improve medication safety and pharmacy workflows.

"Hospitals are embracing innovation not simply to address today's pressures, but to position themselves for the future," said Shahram Hejazi, PhD, CEO of BioAdvance. "Bainbridge's ability to automate workflows that have long relied on manual effort is exactly the kind of step forward that strengthens care delivery."

Real-World Data and the Next Wave of Pharma Innovation

But Bainbridge's impact doesn't stop at the hospital. Pharmaceutical development is also entering a new phase, one where AI-enabled use of real-world clinical data is helping companies select, design, and advance therapies that meet actual demand.

Bainbridge Health is pioneering this approach. Through partnerships with dozens of global Life Sciences and Pharmaceutical manufacturers, Bainbridge Health is helping to identify, validate, and bring to market the next generation of pharmaceutical products that are safer and more efficient for hospitals and the patients they serve. By leveraging demand-side insights from hospitals and linking them directly to supply-side research and development, Bainbridge is enabling this next wave of pharmaceutical products. Ultimately, Bainbridge's goal is to bring to market new, ready-to-use, value-added medications that make life easier for the hospitals they serve.

Proof in Growth and Scale

The adoption of Bainbridge's solutions underscores the momentum behind this shift. In the first half of this year alone, the company nearly doubled its hospital footprint. They recently welcomed multiple medical device manufacturers, including Eitan Medical and B. Braun Medical, to their National Infusion Collaborative™.

"We founded Bainbridge Health in 2016 to help solve pharmacies' biggest challenges," said Joseph Kaupp, Co-Founder and CEO of Bainbridge Health. "At the time, we served a single hospital facility with 500 inpatient beds. Today, our scope has expanded significantly. We are proud to serve over 600 hospitals with over 120,000 beds across 43 states. And our growing partnerships with dozens of pharmaceutical and medical device manufacturers reflect our belief that to truly solve problems, solutions must move upstream. Our goal is to positively impact every node of the pharmacy supply chain."

What This Means for Healthcare

The future of healthcare will be built on productivity, safety, and smarter decision-making. AI-powered automation will enable providers to maximize their resources, while AI-driven insights from real-world data will guide the therapies brought to market, ultimately resulting in better patient care.

"What excites us about Bainbridge is not just their growth, but their vision," said Hejazi. "They understand the forces reshaping healthcare and have built solutions that deliver measurable positive impact. That's exactly the kind of innovation we want to support."

BioAdvance is a regionally focused, evergreen fund created to accelerate transformative innovation in human life sciences. It invests in early-stage companies that are developing cutting-edge therapeutics, digital health solutions, devices, and diagnostics in the Mid-Atlantic region of the US. By supporting entrepreneurs in these companies, and with decades of scientific and industry experience, BioAdvance helps bring disruptive technologies to market-advancing patient care, improving health outcomes, and opening doors to follow-on funding through venture and public capital, strategic partnerships, grants, and acquisitions.